The platelet function as a biomarker for early diagnosis and a course parameter of sepsis

• Conditions: A41; Other sepsis

• Registration Number: DRKS00015485
• Lead Sponsor: Knappschaftskrankenhaus Bochum-Langendreer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-20
• Study Completion: 2019-07-22
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

1. Diagnosed Sepsis due to the Sepsis III Definition And
2. At least two fullfilled SIRS (Systemic inflammatory response syndrome) criteria

Exclusion Criteria

1. Antiplatelet therapy (ASS, ADP-receptor-antagonists and GPIIb/IIIa antagonists) and/or NSAR (non-steroidal anti-inflammatories) in the last four weeks
2. Age < 18 years
3. Congenital or acquired thrombocytopathies
4. Status after splenectomy
5. Pregnancy
6. Immunosuppressive therapy (Chemotherapy, transplant patients)
7. Diagnosed heparin induced thrombocytopenia (HIT 1 or 2)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical evaluation of the collagen activated platelet function on day 0, 1, 2, 3, 4, 5, 8, 11, 14 after a diagnosed sepsis

Secondary Outcome Measures

Name	Time	Method
1. Clinical evaluation of the ADP (adenosine diphosphate), thromboxane, and glycoprotein activated platelet function on day 0, 1, 2, 3, 4, 5, 8, 11, 14 after a diagnosed sepsis<br>2. Determining the predictive value, as well as the specificity and the sensitivity of collagen as a platelet activating substance<br>3. Compare the acquired date with other laboratory values for sepsis (PCT, CRP, leukocytes)<br>4. Analyse the correlation between the above mentioned parameters and further microbiological examination (blood cultures, tracheal secretion, urine) in the course of detecting the root of an infection<br>